David W. J. Mcgirr

David W. J. Mcgirr (board member) discloses dealings in 6 companies, chiefly Cubist Pharmaceuticals Inc, INSMED Inc and Relypsa Inc. Between 9 January 2006 and 23 June 2026, the trades on record add up to 93 filings.

In open-market terms, that means 2 purchases worth €144k on one side and 35 sales worth €9.0M on the other. Taken together, the sales exceed the purchases by €8.8M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Other entries cover 19 share grants and 22 option exercises.

On 25 June 2026 came the latest disclosure, an option exercise in Rhythm Pharmaceuticals, Inc. The clock since the last published purchase (17 November 2014) now reads 4,358 days. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.